Etienne Delgrange1, Alexandre Vasiljevic2, Anne Wierinckx3, Patrick François4, Emmanuel Jouanneau2, Gérald Raverot2, Jacqueline Trouillas2. 1. Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Etienne.delgrange@uclouvain.be. 2. Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France. 3. Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France. 4. Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.
Abstract
CONTEXT: A sex difference in the progression of prolactin (PRL) tumors has been disputed for years. OBJECTIVE: To compare tumor characteristics and postoperative clinical course between men and women, and correlate data with estrogen receptor alpha (ERα (ESR1)) expression status. DESIGN, PATIENTS, AND METHODS: Eighty-nine patients (59 women and 30 men) operated on for a prolactinoma and followed for at least 5 years were selected. Tumors were classified into five grades according to their size, invasion, and proliferation characteristics. The ERα expression was detected by immunohistochemistry and a score (0-12) calculated as the product of the percentage of positive nuclei and the staining intensity. RESULTS: We found a significant preponderance of high-grade tumors among men and a lower surgical cure rate in men (23%) than in women (71%). Patients resistant to medical treatment were mainly men (7/8), six of whom showed tumor progression despite postoperative medical treatment, which led to multiple therapies and eventually death in three. The median score for ERα expression was 1 in men (range, 0-8) and 8 in women (range, 0-12) (P<0.0001). The expression of ERα was inversely correlated with tumor size (r=-0.59; P<0.0001) and proliferative activity. All dopamine agonist-resistant tumors and all grade 2b (invasive and proliferative) tumors (from ten men and four women) were characterized by low ERα expression. CONCLUSIONS: PRL tumors in men are characterized by lower ERα expression, which is related to higher tumor grades, resistance to treatment, and an overall worse prognosis.
CONTEXT: A sex difference in the progression of prolactin (PRL) tumors has been disputed for years. OBJECTIVE: To compare tumor characteristics and postoperative clinical course between men and women, and correlate data with estrogen receptor alpha (ERα (ESR1)) expression status. DESIGN, PATIENTS, AND METHODS: Eighty-nine patients (59 women and 30 men) operated on for a prolactinoma and followed for at least 5 years were selected. Tumors were classified into five grades according to their size, invasion, and proliferation characteristics. The ERα expression was detected by immunohistochemistry and a score (0-12) calculated as the product of the percentage of positive nuclei and the staining intensity. RESULTS: We found a significant preponderance of high-grade tumors among men and a lower surgical cure rate in men (23%) than in women (71%). Patients resistant to medical treatment were mainly men (7/8), six of whom showed tumor progression despite postoperative medical treatment, which led to multiple therapies and eventually death in three. The median score for ERα expression was 1 in men (range, 0-8) and 8 in women (range, 0-12) (P<0.0001). The expression of ERα was inversely correlated with tumor size (r=-0.59; P<0.0001) and proliferative activity. All dopamine agonist-resistant tumors and all grade 2b (invasive and proliferative) tumors (from ten men and four women) were characterized by low ERα expression. CONCLUSIONS: PRL tumors in men are characterized by lower ERα expression, which is related to higher tumor grades, resistance to treatment, and an overall worse prognosis.
Authors: C Villa; A Vasiljevic; M L Jaffrain-Rea; O Ansorge; S Asioli; V Barresi; L Chinezu; M P Gardiman; A Lania; A M Lapshina; L Poliani; L Reiniger; A Righi; W Saeger; J Soukup; M Theodoropoulou; S Uccella; J Trouillas; F Roncaroli Journal: Virchows Arch Date: 2019-10-02 Impact factor: 4.064
Authors: Ryan M Carey; Edward C Kuan; Alan D Workman; Neil N Patel; Michael A Kohanski; Charles C L Tong; Jinbo Chen; James N Palmer; Nithin D Adappa; Jason A Brant Journal: J Neurol Surg B Skull Base Date: 2019-03-15